We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Health Canada has launched an online public database of information relating to drug company inspections, including which firms have a good history of meeting safety and quality standards and which do not. Read More
New hepatitis C treatments were the biggest driver of specialty drug spending growth in the U.S. last year, helping to push total outlays on prescription drugs to $374 billion, the IMS Health Institute for Healthcare Informatics reports. Read More
The FDA is offering a grant of up to $1 million to turn large amounts of electronic health record data into usable figures highlighting postmarket risks of various drugs. The goal is for the agency to be able to perform continuous risk/benefit assessments of drugs after they hit the market. Read More
Mylan has settled patent litigation related to Pfizer’s Viagra, paving the way for generic copies of the erectile dysfunction blockbuster in the U.S. in 19 months. Read More
The Medicines Company’s Kengreal may be on the road to approval, with FDA reviewers backing its use as a post-angioplasty anticlotting agent one year after the agency rejected the drug for this and another indication. Read More
A drug safety committee in the EU is recommending that manufacturers of ibuprofen be required to warn patients that taking the painkiller in high doses is associated with an increased risk of cardiovascular death. Read More
Japan’s drug authority will grant conditional approval to human embryonic and somatic stem cell therapies based on limited clinical data, under a new approval pathway meant to speed patient access to innovative products. Read More